This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gilbert, L. Articles by Nanes, M. S. Search for Related Content PubMed PubMed Citation Articles by Gilbert, L. Articles by Nanes, M. S.

Inhibition of Osteoblast Differentiation by Tumor Necrosis Factor-¹

Division of Endocrinology and Metabolism (L.G., X.H., P.F., M.K., J.R., M.S.N.), Department of Medicine and Department of Orthopedics (S.B.), Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia 30033

Address all correspondence and requests for reprints to: Mark S. Nanes, M.D., Ph.D., VA Medical Center (mail code 111), 1670 Clairmont Road, Decatur, Georgia 30033. E-mail: mnanes{at}emory.edu

Tumor necrosis factor- (TNF-) has a key role in skeletal disease in which it promotes reduced bone formation by mature osteoblasts and increased osteoclastic resorption. Here we show that TNF inhibits differentiation of osteoblasts from precursor cells. TNF- treatment of fetal calvaria precursor cells, which spontaneously differentiate to the osteoblast phenotype over 21 days, inhibited differentiation as shown by reduced formation of multilayered, mineralizing nodules and decreased secretion of the skeletal-specific matrix protein osteocalcin. The effect of TNF was dose dependent with an IC₅₀ of 0.6 ng/ml, indicating a high sensitivity of these precursor cells. Addition of TNF- from days 2–21, 2–14, 7–14, and 7–10 inhibited nodule formation but addition of TNF after day 14 had no effect. Partial inhibition of differentiation was observed with addition of TNF on only days 7–8, suggesting that TNF could act during a critical period of phenotype selection. Growth of cells on collagen-coated plates did not prevent TNF inhibition of differentiation, suggesting that inhibition of collagen deposition into matrix by proliferating cells could not, alone, explain the effect of TNF. Northern analysis revealed that TNF inhibited the expression of insulin-like growth factor I (IGF-I). TNF had no effect on expression of the osteogenic bone morphogenic proteins (BMPs-2, -4, and -6), or skeletal LIM protein (LMP-1), as determined by semiquantitative RT-PCR. Addition of IGF-I or BMP-6 to fetal calvaria precursor cell cultures enhanced differentiation but could not overcome TNF inhibition, suggesting that TNF acted downstream of these proteins in the differentiation pathway. The clonal osteoblastic cell line, MC3T3-E1–14, which acquires the osteoblast phenotype spontaneously in postconfluent culture, was also studied. TNF inhibited differentiation of MC3T3-E1–14 cells as shown by failure of mineralized matrix formation in the presence of calcium and phosphate. TNF was not cytotoxic to either cell type as shown by continued attachment and metabolism in culture, trypan blue exclusion, and Alamar Blue cytotoxicity assay. These results demonstrate that TNF- is a potent inhibitor of osteoblast differentiation and suggest that TNF acts distal to IGF-I, BMPs, and LMP-1 in the progression toward the osteoblast phenotype.

This article has been cited by other articles:

				R Hardy and M S Cooper Bone loss in inflammatory disorders J. Endocrinol., June 1, 2009; 201(3): 309 - 320. [Abstract] [Full Text] [PDF]

				D. Morimoto, S. Kuroda, T. Kizawa, K. Nomura, C. Higuchi, H. Yoshikawa, and T. Tomita Equivalent osteoblastic differentiation function of human mesenchymal stem cells from rheumatoid arthritis in comparison with osteoarthritis Rheumatology, June 1, 2009; 48(6): 643 - 649. [Abstract] [Full Text] [PDF]

				R. Guo, M. Yamashita, Q. Zhang, Q. Zhou, D. Chen, D. G. Reynolds, H. A. Awad, L. Yanoso, L. Zhao, E. M. Schwarz, et al. Ubiquitin Ligase Smurf1 Mediates Tumor Necrosis Factor-induced Systemic Bone Loss by Promoting Proteasomal Degradation of Bone Morphogenetic Signaling Proteins J. Biol. Chem., August 22, 2008; 283(34): 23084 - 23092. [Abstract] [Full Text] [PDF]

				J. Lorenzo, M. Horowitz, and Y. Choi Osteoimmunology: Interactions of the Bone and Immune System Endocr. Rev., June 1, 2008; 29(4): 403 - 440. [Abstract] [Full Text] [PDF]

				X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, J. Sieper, and J. Braun Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-{alpha} antibody infliximab Rheumatology, September 1, 2007; 46(9): 1450 - 1453. [Abstract] [Full Text] [PDF]

				X. Lu, L. Gilbert, X. He, J. Rubin, and M. S. Nanes Transcriptional Regulation of the Osterix (Osx, Sp7) Promoter by Tumor Necrosis Factor Identifies Disparate Effects of Mitogen-activated Protein Kinase and NF{kappa}B Pathways J. Biol. Chem., March 10, 2006; 281(10): 6297 - 6306. [Abstract] [Full Text] [PDF]

				H. Kaneki, R. Guo, D. Chen, Z. Yao, E. M. Schwarz, Y. E. Zhang, B. F. Boyce, and L. Xing Tumor Necrosis Factor Promotes Runx2 Degradation through Up-regulation of Smurf1 and Smurf2 in Osteoblasts J. Biol. Chem., February 17, 2006; 281(7): 4326 - 4333. [Abstract] [Full Text] [PDF]

				L. C. Gilbert, J. Rubin, and M. S. Nanes The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E1011 - E1018. [Abstract] [Full Text] [PDF]

				K. Redlich, B. Gortz, S. Hayer, J. Zwerina, N. Doerr, P. Kostenuik, H. Bergmeister, G. Kollias, G. Steiner, J. S. Smolen, et al. Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis Am. J. Pathol., February 1, 2004; 164(2): 543 - 555. [Abstract] [Full Text] [PDF]

				R. Sitcheran, P. C. Cogswell, and A. S. Baldwin Jr. NF-{kappa}B mediates inhibition of mesenchymal cell differentiation through a posttranscriptional gene silencing mechanism Genes & Dev., October 1, 2003; 17(19): 2368 - 2373. [Abstract] [Full Text] [PDF]

				A. Moralez, W. H. Busby Jr., and D. Clemmons Control of Insulin-Like Growth Factor Binding Protein-5 Protease Synthesis and Secretion by Human Fibroblasts and Porcine Aortic Smooth Muscle Cells Endocrinology, June 1, 2003; 144(6): 2489 - 2495. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz Changes in Proinflammatory Cytokine Activity after Menopause Endocr. Rev., February 1, 2002; 23(1): 90 - 119. [Abstract] [Full Text] [PDF]

				K. Kurokouchi, C. R. Jacobs, and H. J. Donahue Oscillating Fluid Flow Inhibits TNF-alpha -induced NF-kappa B Activation via an Ikappa B Kinase Pathway in Osteoblast-like UMR106 Cells J. Biol. Chem., April 13, 2001; 276(16): 13499 - 13504. [Abstract] [Full Text] [PDF]

				L. Gilbert, X. He, P. Farmer, J. Rubin, H. Drissi, A. J. van Wijnen, J. B. Lian, G. S. Stein, and M. S. Nanes Expression of the Osteoblast Differentiation Factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) Is Inhibited by Tumor Necrosis Factor-alpha J. Biol. Chem., January 18, 2002; 277(4): 2695 - 2701. [Abstract] [Full Text] [PDF]